Pretransfusion Testing: Study Guide
Introduction: The Bedrock of Transfusion Safety
Pretransfusion testing, often broadly referred to as Compatibility Testing, is arguably the single
most critical sequence of steps performed in immunohematology. It serves as the final serologic
safeguard against immune-mediated adverse events. In a clinical environment where blood
transfusion represents the introduction of foreign cellular components (a form of
transplantation), meticulous adherence to testing protocols is vital to ensure that donor blood
components are safe and efficacious for the intended recipient.
The importance of this topic cannot be overstated, as clerical errors leading to ABO
incompatibility remain a primary cause of fatal acute hemolytic transfusion reactions (AHTRs).
Therefore, mastery of pretransfusion testing principles is essential for all medical laboratory
scientists and healthcare professionals involved in the transfusion chain, from phlebotomy to
administration.
1. Definition and Overview
Pretransfusion testing is defined as the application of serologic principles and laboratory tests
designed to predict compatibility between donor RBCs and the recipient’s serum or plasma,
thereby preventing a destructive immune response. Compatibility testing ensures that the donor
RBCs are compatible with the recipient’s serum.
Essential Steps in Pretransfusion Testing
The integrity of the pretransfusion testing process relies on a stringent adherence to standardized
sequential procedures. Key steps include:
1. Request for Transfusion.
2. Positive Patient Identification and Specimen Collection.
3. Evaluation of Specimen Suitability.
4. Recipient Testing (ABO group, Rh type, unexpected antibody screening).
5. Comparison of Current and Previous Test Results.
6. Selection of Donor Units.
7. Final Crossmatch (Serologic or Computerized).
Specimen Requirements and Validity
Page 1 of 15
, • Positive Patient Identification must be performed at the bedside by the collecting
healthcare worker, comparing the patient's name on the armband to the specimen label to
prevent potentially fatal clerical errors.
• Specimen labels must contain two unique identifiers.
• Specimen Validity Period: If a patient has been transfused or pregnant within the past 3
months, or if the history is unknown, the specimen collected for antibody screening and
compatibility testing is only valid for 3 days (collection day is considered Day 0). This
strict standard ensures that recently acquired alloantibodies are detected.
2. Core Principles
The primary goal of pretransfusion testing is to perform ABO grouping, Rh typing, unexpected
antibody screening, and the final crossmatch.
2.1 ABO/Rh Determination
ABO Grouping The ABO system is the most critical due to the presence of naturally occurring,
expected isoagglutinins (Anti-A, Anti-B) in the serum of individuals lacking the corresponding
antigen. These antibodies are typically IgM and can cause immediate intravascular hemolysis if
incompatible blood is transfused.
• Forward Grouping: Detects antigens (A and B) on the patient’s red cells using known
commercial antisera.
• Reverse Grouping (Serum Grouping): Detects expected ABO antibodies in the
patient’s serum or plasma using known reagent A1 and B cells. This test serves as a
confirmation of results by checking for the inverse reciprocal relationship between
antigens and antibodies (e.g., Group A cells express A antigen and serum contains Anti-
B).
Rh Typing (D Antigen) RhD typing is a critical component of pretransfusion and prenatal
testing. The D antigen is the most immunogenic non-ABO antigen.
• Recipient Testing: Patients must be tested for the D antigen, but additional testing for
Weak D is optional.
• Donor Testing: Blood suppliers are required to perform a Weak D test if the initial Rh
typing is negative, because even the smallest amount of D antigen may stimulate an
immune response in an Rh-negative recipient. Donor units testing Weak D-positive must
be labeled as Rh-positive.
2.2 Unexpected Antibody Screening
This test uses commercially prepared screening cells to detect unexpected antibodies directed
against non-ABO red blood cell antigens.
Page 2 of 15
, • Clinical Significance: Antibodies detected are classified as clinically significant if they
have been associated with red blood cell destruction, hemolytic transfusion reactions
(HTR), or hemolytic disease of the fetus and newborn (HDFN). These antibodies are
typically IgG, react best in the antiglobulin phase, and often include antibodies against
antigens such as Rh, Kell (K), Duffy (Fy), and Kidd (Jk).
• Regulatory Requirement: FDA mandates that reagent screening cells must express
specific antigens, including D, C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, S, and s, among others.
2.3 The Crossmatch
The crossmatch is the final test that checks for compatibility between the recipient and the
specific donor unit selected for transfusion.
Serologic Crossmatch
The serologic crossmatch involves mixing the recipient’s serum/plasma with a suspension of
the donor's red blood cells.
Computer (Electronic) Crossmatch
The computer crossmatch is an alternative method that relies on a validated laboratory
information system to verify ABO and Rh compatibility. This method is permitted if the
recipient's ABO and Rh results and the donor unit's ABO and Rh results have been entered twice
into the LIS, and the patient has no history of or current detection of clinically significant
unexpected antibodies. The LIS must include logic that alerts the user of any discrepancies
between recipient records and the donor unit.
3. Common Problems, Errors, or Variations
Failures in pretransfusion testing can originate from administrative, pre-analytical, or technical
phases. The consequences range from test invalidity to patient fatality.
3.1 Clerical and Identification Errors
The most dangerous errors are clerical errors and subsequent ABO incompatibility, which are
cited as the most common cause of fatal AHTRs. Errors include phlebotomy, testing errors,
administration to the wrong recipient, or issuance of the wrong donor unit.
3.2 Technical Errors in Antiglobulin Testing (AGT)
The Antiglobulin Test (AGT), including the Indirect Antiglobulin Test (IAT) used in antibody
screens/crossmatches, is sensitive to technical variations.
Page 3 of 15
, Common Mistake Consequence (False Result)
Inadequate Washing (in AGT) False Negative. Unbound globulins neutralize
the Antihuman Globulin (AHG) reagent.
Failure to Add Reagent (e.g., AHG or serum) False Negative. Test is invalid.
Using Clotted/Refrigerated Samples for DAT False Positive DAT. Complement may attach
in vitro at cold temperatures.
Cord Blood Contamination False Positive (Rouleaux) in Forward
Grouping due to Wharton’s jelly.
Improper Patient ID/Labeling Fatal ABO Incompatibility (Clerical error).
3.3 ABO Discrepancies
An ABO Discrepancy occurs when the forward grouping results do not match the expected
results based on the reverse grouping. The ABO group cannot be reported until the discrepancy
is resolved.
• Group I Discrepancies (Weak/Missing Antibodies): Often seen in elderly patients who
exhibit entirely nonreactive reverse grouping.
• Group III Discrepancies (Protein/Plasma Problems): Often caused by rouleaux
formation due to elevated plasma proteins (e.g., Multiple Myeloma), which can be
misidentified as agglutination.
4. Preventive and Corrective Strategies
Mitigating risks in pretransfusion testing requires strict operational control, validation, and a
focus on human factors that drive clerical error.
4.1 Positive Patient Identification and Specimen Control
Adherence to Standard Operating Procedures (SOPs) for patient identification and specimen
handling is the single most important preventive strategy against fatal transfusion reactions.
Critical Specimen Collection Checklist:
• Verification: Perform positive patient identification at the bedside, comparing the patient
wristband to the specimen label.
• Labeling: Ensure the specimen request and label contain two unique patient identifiers
(e.g., full name and hospital/SSN number). Writing must be legible and indelible.
• Sample Type for DAT: Collect blood samples intended for the Direct Antiglobulin Test
(DAT) in EDTA tubes to prevent in vitro attachment of complement that can cause false
positive results in clotted or refrigerated specimens.
• Validity: Respect the strict 3-day validity window for compatibility testing for recently
transfused or pregnant patients.
Page 4 of 15
Introduction: The Bedrock of Transfusion Safety
Pretransfusion testing, often broadly referred to as Compatibility Testing, is arguably the single
most critical sequence of steps performed in immunohematology. It serves as the final serologic
safeguard against immune-mediated adverse events. In a clinical environment where blood
transfusion represents the introduction of foreign cellular components (a form of
transplantation), meticulous adherence to testing protocols is vital to ensure that donor blood
components are safe and efficacious for the intended recipient.
The importance of this topic cannot be overstated, as clerical errors leading to ABO
incompatibility remain a primary cause of fatal acute hemolytic transfusion reactions (AHTRs).
Therefore, mastery of pretransfusion testing principles is essential for all medical laboratory
scientists and healthcare professionals involved in the transfusion chain, from phlebotomy to
administration.
1. Definition and Overview
Pretransfusion testing is defined as the application of serologic principles and laboratory tests
designed to predict compatibility between donor RBCs and the recipient’s serum or plasma,
thereby preventing a destructive immune response. Compatibility testing ensures that the donor
RBCs are compatible with the recipient’s serum.
Essential Steps in Pretransfusion Testing
The integrity of the pretransfusion testing process relies on a stringent adherence to standardized
sequential procedures. Key steps include:
1. Request for Transfusion.
2. Positive Patient Identification and Specimen Collection.
3. Evaluation of Specimen Suitability.
4. Recipient Testing (ABO group, Rh type, unexpected antibody screening).
5. Comparison of Current and Previous Test Results.
6. Selection of Donor Units.
7. Final Crossmatch (Serologic or Computerized).
Specimen Requirements and Validity
Page 1 of 15
, • Positive Patient Identification must be performed at the bedside by the collecting
healthcare worker, comparing the patient's name on the armband to the specimen label to
prevent potentially fatal clerical errors.
• Specimen labels must contain two unique identifiers.
• Specimen Validity Period: If a patient has been transfused or pregnant within the past 3
months, or if the history is unknown, the specimen collected for antibody screening and
compatibility testing is only valid for 3 days (collection day is considered Day 0). This
strict standard ensures that recently acquired alloantibodies are detected.
2. Core Principles
The primary goal of pretransfusion testing is to perform ABO grouping, Rh typing, unexpected
antibody screening, and the final crossmatch.
2.1 ABO/Rh Determination
ABO Grouping The ABO system is the most critical due to the presence of naturally occurring,
expected isoagglutinins (Anti-A, Anti-B) in the serum of individuals lacking the corresponding
antigen. These antibodies are typically IgM and can cause immediate intravascular hemolysis if
incompatible blood is transfused.
• Forward Grouping: Detects antigens (A and B) on the patient’s red cells using known
commercial antisera.
• Reverse Grouping (Serum Grouping): Detects expected ABO antibodies in the
patient’s serum or plasma using known reagent A1 and B cells. This test serves as a
confirmation of results by checking for the inverse reciprocal relationship between
antigens and antibodies (e.g., Group A cells express A antigen and serum contains Anti-
B).
Rh Typing (D Antigen) RhD typing is a critical component of pretransfusion and prenatal
testing. The D antigen is the most immunogenic non-ABO antigen.
• Recipient Testing: Patients must be tested for the D antigen, but additional testing for
Weak D is optional.
• Donor Testing: Blood suppliers are required to perform a Weak D test if the initial Rh
typing is negative, because even the smallest amount of D antigen may stimulate an
immune response in an Rh-negative recipient. Donor units testing Weak D-positive must
be labeled as Rh-positive.
2.2 Unexpected Antibody Screening
This test uses commercially prepared screening cells to detect unexpected antibodies directed
against non-ABO red blood cell antigens.
Page 2 of 15
, • Clinical Significance: Antibodies detected are classified as clinically significant if they
have been associated with red blood cell destruction, hemolytic transfusion reactions
(HTR), or hemolytic disease of the fetus and newborn (HDFN). These antibodies are
typically IgG, react best in the antiglobulin phase, and often include antibodies against
antigens such as Rh, Kell (K), Duffy (Fy), and Kidd (Jk).
• Regulatory Requirement: FDA mandates that reagent screening cells must express
specific antigens, including D, C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, S, and s, among others.
2.3 The Crossmatch
The crossmatch is the final test that checks for compatibility between the recipient and the
specific donor unit selected for transfusion.
Serologic Crossmatch
The serologic crossmatch involves mixing the recipient’s serum/plasma with a suspension of
the donor's red blood cells.
Computer (Electronic) Crossmatch
The computer crossmatch is an alternative method that relies on a validated laboratory
information system to verify ABO and Rh compatibility. This method is permitted if the
recipient's ABO and Rh results and the donor unit's ABO and Rh results have been entered twice
into the LIS, and the patient has no history of or current detection of clinically significant
unexpected antibodies. The LIS must include logic that alerts the user of any discrepancies
between recipient records and the donor unit.
3. Common Problems, Errors, or Variations
Failures in pretransfusion testing can originate from administrative, pre-analytical, or technical
phases. The consequences range from test invalidity to patient fatality.
3.1 Clerical and Identification Errors
The most dangerous errors are clerical errors and subsequent ABO incompatibility, which are
cited as the most common cause of fatal AHTRs. Errors include phlebotomy, testing errors,
administration to the wrong recipient, or issuance of the wrong donor unit.
3.2 Technical Errors in Antiglobulin Testing (AGT)
The Antiglobulin Test (AGT), including the Indirect Antiglobulin Test (IAT) used in antibody
screens/crossmatches, is sensitive to technical variations.
Page 3 of 15
, Common Mistake Consequence (False Result)
Inadequate Washing (in AGT) False Negative. Unbound globulins neutralize
the Antihuman Globulin (AHG) reagent.
Failure to Add Reagent (e.g., AHG or serum) False Negative. Test is invalid.
Using Clotted/Refrigerated Samples for DAT False Positive DAT. Complement may attach
in vitro at cold temperatures.
Cord Blood Contamination False Positive (Rouleaux) in Forward
Grouping due to Wharton’s jelly.
Improper Patient ID/Labeling Fatal ABO Incompatibility (Clerical error).
3.3 ABO Discrepancies
An ABO Discrepancy occurs when the forward grouping results do not match the expected
results based on the reverse grouping. The ABO group cannot be reported until the discrepancy
is resolved.
• Group I Discrepancies (Weak/Missing Antibodies): Often seen in elderly patients who
exhibit entirely nonreactive reverse grouping.
• Group III Discrepancies (Protein/Plasma Problems): Often caused by rouleaux
formation due to elevated plasma proteins (e.g., Multiple Myeloma), which can be
misidentified as agglutination.
4. Preventive and Corrective Strategies
Mitigating risks in pretransfusion testing requires strict operational control, validation, and a
focus on human factors that drive clerical error.
4.1 Positive Patient Identification and Specimen Control
Adherence to Standard Operating Procedures (SOPs) for patient identification and specimen
handling is the single most important preventive strategy against fatal transfusion reactions.
Critical Specimen Collection Checklist:
• Verification: Perform positive patient identification at the bedside, comparing the patient
wristband to the specimen label.
• Labeling: Ensure the specimen request and label contain two unique patient identifiers
(e.g., full name and hospital/SSN number). Writing must be legible and indelible.
• Sample Type for DAT: Collect blood samples intended for the Direct Antiglobulin Test
(DAT) in EDTA tubes to prevent in vitro attachment of complement that can cause false
positive results in clotted or refrigerated specimens.
• Validity: Respect the strict 3-day validity window for compatibility testing for recently
transfused or pregnant patients.
Page 4 of 15
